Advanced Filters
noise

Woods Cross, Utah Clinical Trials

A listing of Woods Cross, Utah clinical trials actively recruiting patient volunteers.

Found 427 clinical trials
U Umang Swami

Optimal PSA Triggered Individual Management of Androgen Sensitive Prostate Cancer

The purpose of this study is to evaluate intermittent relugolix + androgen receptor pathway inhibitor (ARPI) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) achieving optimal PSA response.

18 years of age Male Phase 2
F Flory Nkoy, MD, MS, MPH

A Novel mHealth Intervention to Improve Outcomes of Children With Medical Complexity

Children with medical complexity (CMC) are the most vulnerable of children with chronic diseases, who have complex, multisystem chronic diseases affecting ≥3 organ systems, severe functional limitations and technology dependencies. CMC have high health care needs, and account for 40% of hospitalized children and 35% of all pediatric health care …

1 - 18 years of age All Phase N/A

JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration

This study is to evaluate the safety and tolerability of pan-KRAS inhibitor JAB-23E73 in adult participants with advanced solid tumors

18 years of age All Phase 1/2
U Umang Swami

Bortezomib in Patients With Metastatic Castration-Resistant Prostate Cancer With PTEN Deletion

The goal of this clinical trial is to test the anti-tumor activity of bortezomib in participants with Metastatic Castration Resistant Prostate Cancer (mCRPC) with PTEN Deletion. The main question[s] it aims to answer is if the use of bortezomib will result in a decline in PSA for participants. Participants will …

18 years of age Male Phase 2
J Joseph E. Tonna, MD, FAAEM

Physiology of Unloading VA ECMO Trial

The goal of this clinical trial is to compare the use of veno-arterial extracorporeal membrane oxygenation (VA ECMO) with and without left ventricular (LV) unloading in patients being treated for non-postoperative cardiogenic shock (CS). The main aims of the study are: To determine the physiologic effects on cardiopulmonary congestion of …

18 years of age All Phase 2
L Linda Wheeler

OPN-375 Efficacy and Safety in Adolescents With Bilateral Nasal Polyps

This is a 16-Week Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of OPN-375 186 μg Twice a Day (BID) in Adolescents with Bilateral Nasal Polyps followed by a 12-Week Open-Label Treatment Phase. The total planned number of subjects is approximately 120 adolescents (12-17 years of …

12 - 17 years of age All Phase 3
M Marcela Smid, MD

Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder

The primary objective of this research study is to evaluate the effect of tirzepatide, relative to placebo, as an adjunct to BUP on retention, substance use, and sleep outcomes in individuals with OUD.

18 years of age All Phase 2
U US GSK Clinical Trials Call Center

Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial

This is a 52-week, randomized, placebo-controlled, double-blind, parallel group, multicenter study of depemokimab in adults with uncontrolled HES receiving standard of care (SoC) therapy. The study will recruit patients with a confirmed diagnosis of HES and who are on stable HES therapy for at least 4 weeks prior to randomization …

18 years of age All Phase 3

Contraceptive Efficacy Study of Ovaprene

This will be a multi-center, single arm, open-label study of Ovaprene, a non-hormonal intravaginal ring, to investigate the contraceptive effectiveness, safety and acceptability of Ovaprene.

18 - 40 years of age Female Phase N/A
A Alison Brand

Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER

This protocol tests de-escalated adjuvant treatment in patients with POLE-mutated or p53wt/NSMP (p53 wildtype/no specific molecular profile) early-stage endometrial cancer (EC). Patients may be enrolled in one of two sub-studies EN10.A/RAINBO BLUE: POLE-mutated EC EN10.B/TAPER: p53 wildtype / NSMP EC

18 years of age Female Phase 2

Simplify language using AI